Skip to main content

Recursion Pharmaceuticals, Inc.

corporate_fare Company Profile

Recursion Pharmaceuticals, Inc.

RXRX·NASDAQ·Life Sciences·CIK 0001601830

Recursion is a clinical-stage TechBio company focused on decoding biology to improve lives. The company uses its integrated drug discovery and development platform, the Recursion Operating System (OS), to power its internal programs and strategic partnerships. This platform offers complete, AI-native capabilities from new biological ideas through clinical development, combining multimodal biological data generation, AI-powered small molecule synthesis, and AI-enabled clinical development. Recursion's technologies are designed to translate complex science into medicines more quickly, effectively, and at scale. Historically, moving a drug discovery project from early discovery to an approved therapeutic has taken over ten years and an average capitalized R&D cost of approximately $2-3.5 billion, with less than 4% of initiated programs resulting in an approved medicine. Recursion aims to transform this traditional "V-shaped" discovery funnel into a 'T-shaped' model by using advanced computational tools across biology, chemistry, and clinical development. The goal is to quickly narrow a broad set of potential medicines to candidates with the highest probabilities of success, moving programs through development more efficiently and with less attrition. Advances in artificial intelligence and machine learning (AI/ML) are increasingly influencing the technology and biopharmaceutical industries, with a majority of large biopharmaceutical companies now using AI/ML in drug discovery or development. Global investment in AI-enabled drug discovery has grown to several billions of dollars annually. Regulators and policymakers are also actively engaged, with AI/ML-enabled approaches applied across multiple stages of drug discovery and development, including target identification, molecular design, chemical synthesis, clinical development, and manufacturing.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for RXRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-02, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for RXRX spans 10-Q, 8-K, 424B5, DEF 14A.

Recent high-impact activity:

  • Recursion Q3: Revenue Beat, $561.5M Cash, Tempus Deal Restructured, Controls Still Weak
  • Recursion Tops Q3 Revenue Estimates and Extends Cash Runway Into 2029
  • Recursion Beats Q3 Revenue Estimates With $18.1M, Narrows Loss
  • REC-4881 Cuts Larger, High-Risk Polyps Across GI Tract in Phase 2 FAP Data
  • REC-4881 Cuts Polyp Burden 87% in Phase 1b/2; Recursion Extends Runway Into 2029

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$74.68M
Net Income
-$644.76M
Diluted EPS
-$1.44
Op. Cash Flow
-$371.81M
Free Cash Flow
-$378.28M
Gross Profit
$3.73M
Operating Income
-$648.13M
Cash & Equivalents
$743.29M
Debt / Equity
0.00×
Net Margin
-8.63×
Shares Outstanding
528.18M sh
Source: 10-K · filed 2026-02-25 · accession 0001601830-26-000039

Short Interest & Short Volume

6.10 days to cover

FINRA reported short interest of 142,265,985 shares in RXRX as of the October 30, 2026 settlement, a 12.1% decrease from the prior period — about 6.1 days to cover at its recent average daily volume. On November 20, 2026, 57.3% of RXRX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)142,265,985 shares as of October 30, 2026
Change vs prior period▼ 12.1%
Days to cover6.10 at avg daily volume of 23,330,471
Daily short volume (FINRA facilities)57.3% of 12,525,167 shares on November 20, 2026
5-day average short volume71.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for RXRX, detected from its recent SEC filings · based on capital-structure filings through 2026-10-15.

1 recent capital raise

Final Terms Confirmed for $200M Offering · Net Proceeds and Fees

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with R →
$2.5 +2.08% today
52-week range · as of 2026-11-02 $2.5 – $5.76
Market cap
$1.53B
Volume
29.9M (1.2× avg)
3-mo avg 25.6M
Live data · 2026-11-21 00:15 UTC · After hours

show_chartPrice Chart

Loading chart...

feed RXRX - Latest Insights

RXRX
Nov 02, 2026, 4:34 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.82
Real-time Price: $2.50 info
Change: -$1.32 (-35%) info
Market Cap: $1.527B info
RXRX
Nov 02, 2026, 4:32 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.83
Real-time Price: $2.50 info
Change: -$1.33 (-35%) info
Market Cap: $1.527B info
RXRX
Nov 02, 2026, 4:31 PM EST
Source: Reuters
Importance Score:
8
Price at Filing: $3.80
Real-time Price: $2.50 info
Change: -$1.30 (-34%) info
Market Cap: $1.527B info
RXRX
Nov 02, 2026, 4:25 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.83
Real-time Price: $2.50 info
Change: -$1.33 (-35%) info
Market Cap: $1.527B info
RXRX
Oct 16, 2026, 3:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $4.17
Real-time Price: $2.50 info
Change: -$1.67 (-40%) info
Market Cap: $1.527B info
RXRX
Oct 15, 2026, 8:46 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.72
Real-time Price: $2.50 info
Change: -$1.22 (-33%) info
Market Cap: $1.527B info
RXRX
Oct 15, 2026, 8:22 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.48
Real-time Price: $2.50 info
Change: -$0.979 (-28%) info
Market Cap: $1.527B info
RXRX
Oct 15, 2026, 8:19 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $3.63
Real-time Price: $2.50 info
Change: -$1.13 (-31%) info
Market Cap: $1.527B info
RXRX
Sep 21, 2026, 9:24 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $3.90
Real-time Price: $2.50 info
Change: -$1.40 (-36%) info
Market Cap: $1.527B info
RXRX
Sep 21, 2026, 9:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.91
Real-time Price: $2.50 info
Change: -$1.41 (-36%) info
Market Cap: $1.527B info
RXRX
Aug 10, 2026, 7:37 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.20
Real-time Price: $2.50 info
Change: -$0.7017 (-22%) info
Market Cap: $1.527B info
RXRX
Aug 05, 2026, 6:42 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $3.03
Real-time Price: $2.50 info
Change: -$0.529 (-17%) info
Market Cap: $1.527B info
RXRX
Aug 05, 2026, 6:32 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.97
Real-time Price: $2.50 info
Change: -$0.469 (-16%) info
Market Cap: $1.527B info
RXRX
Aug 05, 2026, 6:31 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.97
Real-time Price: $2.50 info
Change: -$0.469 (-16%) info
Market Cap: $1.527B info
RXRX
May 06, 2026, 6:32 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.40
Real-time Price: $2.50 info
Change: -$0.894 (-26%) info
Market Cap: $1.527B info
RXRX
May 06, 2026, 6:31 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.36
Real-time Price: $2.50 info
Change: -$0.859 (-26%) info
Market Cap: $1.527B info
RXRX
May 06, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $3.37
Real-time Price: $2.50 info
Change: -$0.869 (-26%) info
Market Cap: $1.527B info
RXRX
Apr 30, 2026, 4:33 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $3.46
Real-time Price: $2.50 info
Change: -$0.9591 (-28%) info
Market Cap: $1.527B info
RXRX
Mar 25, 2026, 4:42 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.15
Real-time Price: $2.50 info
Change: -$0.649 (-21%) info
Market Cap: $1.527B info
RXRX
Feb 25, 2026, 6:44 AM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $4.12
Real-time Price: $2.50 info
Change: -$1.62 (-39%) info
Market Cap: $1.527B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets